Isturisa

Osilodrostat, the active ingredient in Isturisa, is a steroidogenesis inhibitor presented as an oral tablet for oral use. It treats Cushing's disease in patients with endogenous hypercortisolism.

GNH USA supplies Isturisa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isturisa (osilodrostat) is used to manage disorders of cortisol excess, specifically Cushing's disease.

- Cushing's disease: reduces cortisol production and helps control hypercortisolism.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Fatigue: feeling unusually tired. - Headache: intermittent mild pain. - Decreased appetite: reduced desire to eat. - Dizziness: light‑headed sensations. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Adrenal insufficiency: signs of cortisol deficiency such as severe fatigue and hypotension. - Hypokalemia: low potassium levels causing muscle weakness. - QT interval prolongation: potential cardiac rhythm disturbances. - Severe hypertension: markedly high blood pressure requiring urgent care. - Hepatic injury: abnormal liver function tests. - Allergic reactions: rash, swelling, or breathing difficulty.

Before initiating therapy, clinicians should assess baseline cortisol, electrolyte, and blood pressure status.

- Monitor cortisol: regularly check serum cortisol to avoid over‑suppression. - Check electrolytes: watch potassium and sodium levels. - Observe blood pressure: adjust antihypertensive therapy as needed. - Pregnancy safety: use only if potential benefit justifies risk, as data are limited. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Osilodrostat may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce osilodrostat exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drug levels and toxicity. - Concomitant glucocorticoids: can mask adrenal insufficiency.

Moderate Interactions (Monitor Closely): - Antihypertensives: blood pressure may change, requiring dose adjustment. - Potassium‑sparing diuretics: risk of hyperkalemia. - Oral contraceptives: hormonal levels may be altered. - CYP3A4 substrate drugs (e.g., statins): monitor for increased concentrations. - Antifungal azoles (non‑potent): may modestly raise osilodrostat levels.